0001104659-18-002075.txt : 20180112
0001104659-18-002075.hdr.sgml : 20180112
20180112163248
ACCESSION NUMBER: 0001104659-18-002075
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180111
FILED AS OF DATE: 20180112
DATE AS OF CHANGE: 20180112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PATRICK GREGORY S
CENTRAL INDEX KEY: 0001219844
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35518
FILM NUMBER: 18526294
MAIL ADDRESS:
STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC.
STREET 2: 1550 EAST GUDE DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001356576
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 1550 E GUDE DR
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-838-2500
MAIL ADDRESS:
STREET 1: 1550 E GUDE DR
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
a4.xml
4
X0306
4
2018-01-11
0
0001356576
SUPERNUS PHARMACEUTICALS INC
SUPN
0001219844
PATRICK GREGORY S
C/O SUPERNUS PHARMACEUTICALS, INC.
1550 EAST GUDE DRIVE
ROCKVILLE
MD
20850
0
1
0
0
VP, Chief Financial Officer
Common Stock
2018-01-11
4
M
0
25000
5.88
A
55975
D
Common Stock
2018-01-11
4
M
0
20000
7.90
A
75975
D
Common Stock
2018-01-11
4
M
0
30000
9.24
A
105975
D
Common Stock
2018-01-11
4
S
0
50000
43.5629
D
55975
D
Employee Stock Option (Right to Buy)
5.88
2018-01-11
4
M
0
25000
0
D
2021-12-30
Common Stock
25000
0
D
Employee Stock Option (Right to Buy)
7.90
2018-01-11
4
M
0
20000
0
D
2023-02-05
Common Stock
20000
0
D
Employee Stock Option (Right to Buy)
9.24
2018-01-11
4
M
0
30000
0
D
2024-01-21
Common Stock
30000
20000
D
Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017.
Includes an aggregate of 259 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.2500 to $43.8500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The option became exercisable in four equal installments beginning on December 30, 2012, which was the first anniversary of the date on which the option was granted.
The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted.
The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted.
/s/ Gregory S. Patrick
2018-01-12